Intensity Modulated Radiation Therapy for Early-Stage Primary Gastric Diffuse Large B-Cell Lymphoma: Dosimetric Analysis, Clinical Outcome, and Quality of Life

2016 ◽  
Vol 95 (2) ◽  
pp. 712-720 ◽  
Author(s):  
Xin Liu ◽  
Hui Fang ◽  
Yuan Tian ◽  
Wei-Hu Wang ◽  
Yong-Wen Song ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cell Lymphoma ◽  
Early Stage ◽  
Intensity Modulated Radiation Therapy ◽  
B Cell Lymphoma ◽  
Intensity Modulated ◽  
Large B Cell Lymphoma ◽  
Dosimetric Analysis ◽  
Large B Cell

scholarly journals Reply to age-related differences in quality of life among patients with diffuse large B-cell lymphoma

Cancer ◽  
2015 ◽  
Vol 121 (16) ◽  
pp. 2858-2859 ◽  
Author(s):  
Jessica N. Williams ◽  
Ashish Rai ◽  
Christopher R. Flowers
Keyword(s):  
Quality Of Life ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Age Related ◽  
Large B Cell

scholarly journals Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma

2021 ◽  
Vol 5 (8) ◽  
pp. 2245-2255
Author(s):  
Donald L. Patrick ◽  
Annette Powers ◽  
Monika Parisi Jun ◽  
Yeonhee Kim ◽  
Jacob Garcia ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Meaningful Improvement ◽  
Large B Cell Lymphoma ◽  
Car T ◽  
Eortc Qlq C30 ◽  
Eortc Qlq ◽  
Large B Cell

Abstract CD19-directed chimeric antigen receptor (CAR) T-cell therapy has shown efficacy as a third-line or later treatment in patients with relapsed/refractory large B-cell lymphoma (LBCL). Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire, we evaluated the impact of CAR T-cell treatment with lisocabtagene maraleucel (liso-cel) on health-related quality of life (HRQoL) and symptoms in patients with relapsed/refractory LBCL in the ongoing, open-label, nonrandomized TRANSCEND NHL 001 trial. Clinically meaningful improvement was observed in EORTC QLQ-C30 scores for global health status/QoL, based on a minimally important difference of 10 points at 2 to 18 months after liso-cel infusion. There were no clinically meaningful changes in physical functioning and pain, whereas clinically meaningful improvements were observed in fatigue at 2, 12, and 18 months. The proportion of patients with clinically meaningful improvement in global health status/QoL was generally higher for treatment responders than for nonresponders. A trend toward decreased mean EQ-5D-5L index scores was observed at 1 month after liso-cel infusion, followed by subsequent increases through 18 months. Mean EQ-5D-5L visual analog scale scores increased from 2 through 18 months. In summary, patients with relapsed/refractory LBCL treated with liso-cel had early, sustained, and clinically meaningful improvements in HRQoL and symptoms that correlated with antitumor activity. This study was registered at www.clinicaltrials.gov as #NCT02631044.

Sign in / Sign up

Export Citation Format

Share Document